Malhotra Karan, Subramaniyan Mayavan, Rawat Khushboo, Kalamuddin Md, Qureshi M Irfan, Malhotra Pawan, Mohmmed Asif, Cornish Katrina, Daniell Henry, Kumar Shashi
Metabolic Engineering Group, International Centre for Genetic Engineering and Biotechnology, Aruna Asaf Ali Marg, New Delhi 110067, India.
Malaria Research Group, International Centre for Genetic Engineering and Biotechnology, Aruna Asaf Ali Marg, New Delhi 110067, India.
Mol Plant. 2016 Nov 7;9(11):1464-1477. doi: 10.1016/j.molp.2016.09.013. Epub 2016 Oct 20.
Artemisinin is highly effective against drug-resistant malarial parasites, which affects nearly half of the global population and kills >500 000 people each year. The primary cost of artemisinin is the very expensive process used to extract and purify the drug from Artemisia annua. Elimination of this apparently unnecessary step will make this potent antimalarial drug affordable to the global population living in endemic regions. Here we reported the oral delivery of a non-protein drug artemisinin biosynthesized (∼0.8 mg/g dry weight) at clinically meaningful levels in tobacco by engineering two metabolic pathways targeted to three different cellular compartments (chloroplast, nucleus, and mitochondria). The doubly transgenic lines showed a three-fold enhancement of isopentenyl pyrophosphate, and targeting AACPR, DBR2, and CYP71AV1 to chloroplasts resulted in higher expression and an efficient photo-oxidation of dihydroartemisinic acid to artemisinin. Partially purified extracts from the leaves of transgenic tobacco plants inhibited in vitro growth progression of Plasmodium falciparum-infected red blood cells. Oral feeding of whole intact plant cells bioencapsulating the artemisinin reduced the parasitemia levels in challenged mice in comparison with commercial drug. Such novel synergistic approaches should facilitate low-cost production and delivery of artemisinin and other drugs through metabolic engineering of edible plants.
青蒿素对耐药疟原虫非常有效,疟原虫影响着近一半的全球人口,每年导致超过50万人死亡。青蒿素的主要成本在于从黄花蒿中提取和纯化该药物的过程非常昂贵。消除这一明显不必要的步骤将使这种强效抗疟药物能够被生活在疟疾流行地区的全球人口所承受。在此,我们报告了通过对靶向三个不同细胞区室(叶绿体、细胞核和线粒体)的两条代谢途径进行工程改造,在烟草中以具有临床意义的水平生物合成(约0.8毫克/克干重)非蛋白质药物青蒿素并实现口服给药。双转基因品系的异戊烯基焦磷酸增加了三倍,将青蒿酸醛还原酶(AACPR)、二氢青蒿酸还原酶(DBR2)和细胞色素P450 71AV1(CYP71AV1)靶向叶绿体导致更高的表达以及二氢青蒿酸高效光氧化为青蒿素。来自转基因烟草植物叶片的部分纯化提取物抑制了恶性疟原虫感染的红细胞的体外生长进程。与商业药物相比,口服包裹有青蒿素的完整植物细胞降低了受攻击小鼠的疟原虫血症水平。这种新型协同方法应有助于通过可食用植物的代谢工程实现青蒿素和其他药物的低成本生产与给药。